- Home
- OVV vs DVA Comparison
OVV vs DVA Comparison
Compare OVV & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OVV
- DVA
- Stock Information
- Founded
- OVV 2020
- DVA 1994
- Country
- OVV United States
- DVA United States
- Employees
- OVV N/A
- DVA N/A
- Industry
- OVV Oil & Gas Production
- DVA Misc Health and Biotechnology Services
- Sector
- OVV Energy
- DVA Health Care
- Exchange
- OVV Nasdaq
- DVA Nasdaq
- Market Cap
- OVV 10.8B
- DVA 12.6B
- IPO Year
- OVV N/A
- DVA 1995
- Fundamental
- Price
- OVV $37.68
- DVA $151.89
- Analyst Decision
- OVV Buy
- DVA Hold
- Analyst Count
- OVV 17
- DVA 5
- Target Price
- OVV $56.19
- DVA $153.40
- AVG Volume (30 Days)
- OVV 3.1M
- DVA 738.2K
- Earning Date
- OVV 11-07-2024
- DVA 02-11-2025
- Dividend Yield
- OVV 3.18%
- DVA N/A
- EPS Growth
- OVV N/A
- DVA 41.03
- EPS
- OVV 7.54
- DVA 9.24
- Revenue
- OVV $9,562,000,000.00
- DVA $12,666,614,000.00
- Revenue This Year
- OVV N/A
- DVA $6.17
- Revenue Next Year
- OVV N/A
- DVA $3.56
- P/E Ratio
- OVV $5.01
- DVA $16.43
- Revenue Growth
- OVV N/A
- DVA 6.34
- 52 Week Low
- OVV $36.91
- DVA $103.40
- 52 Week High
- OVV $55.95
- DVA $169.52
- Technical
- Relative Strength Index (RSI)
- OVV 29.90
- DVA 43.32
- Support Level
- OVV $41.10
- DVA $145.99
- Resistance Level
- OVV $39.39
- DVA $151.03
- Average True Range (ATR)
- OVV 1.09
- DVA 3.81
- MACD
- OVV -0.64
- DVA -1.32
- Stochastic Oscillator
- OVV 4.56
- DVA 33.57
About OVV Ovintiv Inc. (DE)
Ovintiv is a North American oil and natural gas exploration and production company. It focuses on the exploration and development of oil, NGLs, and natural gas reserves. The company has three segments: USA Operations, Canadian Operations, and Market Optimization.
About DVA DaVita Inc.
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the us, and treats about 250,000 patients globally each year. Government payers dominate us dialysis reimbursement. DaVita receives about two thirds of us sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of the us patients treated, they represent nearly all of the profits generated by DaVita in the us dialysis business.